MedTrace Logo

Oral Bioavailability of Bilastine

NCT01124123 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-09-26

No results posted yet for this study

Summary

The purpose of this study is to assess the absolute bioavailability of an oral bilastine formulation (test drug) compared to the endovenous administration of an IV bilastine formulation (control drug) in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Bilastine

20 mg oral tablet

DRUG

Bilastine

10 mg endovenous bilastine

Sponsors & Collaborators

  • Faes Farma, S.A.

    lead INDUSTRY

Principal Investigators

  • Belen Sadaba, MD · Unidad de Investigacion Clinica. Clinica Universidad Navarra (CUN)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-06-30
Completion
2010-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01124123 on ClinicalTrials.gov